Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background and Purpose</h3><p>Liver fibrosis is one of the leading causes of morbidity and mortality worldwide of which no acceptable therapy exists. Accumulating evidence supports that glioma‐associated oncogene homologue 1 (GLI1) is a potentially important therapeutic target for liver fibrosis. This study investigates the antifibrotic activities and potential mechanisms of Physalin B (PB), a natural Solanaceae compound.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Experimental Approach</h3><p>Mice subjected to carbon tetrachloride (CCl<sub>4</sub>) challenge and bile duct ligation (BDL) were used to study the antifibrotic effects of PB <i>in vivo</i>. Mouse primary hepatic stellate cells (pHSCs) and human HSC line LX‐2 also served as an <i>in vitro</i> liver fibrosis model. Liver fibrogenic genes, GLI1 and GLI1 downstream genes were examined using western blot and quantitative real‐time PCR (qRT‐PCR). GLI1 acetylation and LAP2α‐HDAC1 interaction were analyzed by coimmunoprecipitation. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Key Results</h3><p>In animal models, PB administration attenuated hepatic histopathological injury, collagen accumulation, and reduced the expression of fibrogenic genes. PB dose‐dependently suppressed fibrotic marker expression in LX‐2 cells and mouse pHSCs. Mechanistic studies showed PB inhibited GLI activity in a non‐canonical Hedgehog signaling. PB blocked lamina‐associated polypeptide 2 α (LAP2α)/histone deacetylase 1 (HDAC1) complex formation thereby inhibited HDAC1mediated GLI1 deacetylation. PB upregulated the acetylation of GLI1, downregulated the expression of GLI1 and subsequently inhibiting HSC activation.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions and Implications</h3><p>PB exerted potent antifibrotic effects <i>in vitro</i> and <i>in vivo</i> by disrupting the LAP2α/HDAC1 complex, increasing GLI1 acetylation and inactivating GLI1. This indicates that PB may be a potential therapeutic candidate for the treatment of liver fibrosis. </p></section>

A natural small molecule alleviates liver fibrosis by targeting apolipoprotein L2

Liver Fibrosis Therapy Based on Biomimetic Nanoparticles Which Deplete Activated Hepatic Stellate Cells.

Diisopropylamine Dichloroacetate Alleviates Liver Fibrosis Through Inhibiting Activation And Proliferation Of Hepatic Stellate Cells

Design and Discovery of Novel Cyclic Peptides as EDPs-EBP Interaction Inhibitors for the Treatment of Liver Fibrosis

Identification of linderalactone as a natural inhibitor of SHP2 to ameliorate CCl4-induced liver fibrosis

Discovery of 1,8-naphthalidine derivatives as potent anti-hepatic fibrosis agents via repressing PI3K/AKT/Smad and JAK2/STAT3 pathways

Dihydrotrichodimerol Purified from the Marine Fungus Acremonium citrinum Prevents NAFLD by Targeting PPARα

Design, synthesis, and biological evaluation of piperazine derivatives as pan-PPARs agonists for the treatment of liver fibrosis

Apigenin intervenes in liver fibrosis by regulating PKM2-HIF-1α mediated oxidative stress

Asiatic acid alleviates liver fibrosis via multiple signaling pathways based on integrated network pharmacology and lipidomics

Discovery of Potent Phosphodiesterase-9 Inhibitors for the Treatment of Hepatic Fibrosis

Highly Selective Targeting of Hepatic Stellate Cells for Liver Fibrosis Treatment Using a d-Enantiomeric Peptide Ligand of Fn14 Identified by Mirror-Image mRNA Display.

Ligand‐Tethered Extracellular Vesicles Mediated RNA Therapy for Liver Fibrosis

Discovery of Novel Peptide Antagonists Targeting GPR55 for Liver Inflammation and Fibrosis

The suppression of pancreatic lipase-related protein 2 ameliorates experimental hepatic fibrosis in mice

Novel Inositol 1,4,5-Trisphosphate Receptor Inhibitor Antagonizes Hepatic Stellate Cell Activation: A Potential Drug to Treat Liver Fibrosis

Design, Synthesis, and Antifibrosis Activity in Liver of Nonsecosteroidal Vitamin D Receptor Agonists with Phenyl-pyrrolyl Pentane Skeleton

TGF-β Type I Receptor Kinase Inhibitor EW-7197 Suppresses Cholestatic Liver Fibrosis by Inhibiting HIF1α-Induced Epithelial Mesenchymal Transition

Physalin B attenuates liver fibrosis via suppressing LAP2α–HDAC1‐mediated deacetylation of the transcription factor GLI1 and hepatic stellate cell activation

Design, Synthesis, and Evaluation of Dihydropyrimidine Derivatives as Selective PDE1 Inhibitors for the Treatment of Liver Fibrosis

Local Inhibition of Liver Fibrosis by Specific Delivery of a Platelet-Derived Growth Factor Kinase Inhibitor to Hepatic Stellate Cells